Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

Alzheimers Res Ther. 2021 May 10;13(1):98. doi: 10.1186/s13195-021-00838-z.
No abstract available

Keywords: Aducanumab; Clinical trials; Donanemab; FDA; Gantenerumab; Lecanemab; Monoclonal antibodies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Amyloid
  • Amyloid beta-Peptides
  • Amyloidogenic Proteins
  • Antibodies, Monoclonal, Humanized*
  • Humans

Substances

  • Amyloid
  • Amyloid beta-Peptides
  • Amyloidogenic Proteins
  • Antibodies, Monoclonal, Humanized
  • aducanumab